|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,207,066: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,207,066?
U.S. Patent 10,207,066, granted on April 16, 2019, covers a novel pharmaceutical composition designed for the treatment of specific disease indications. Its claims focus on a class of compounds, methods of manufacturing these compounds, and their use in pharmaceutical formulations.
The patent's broadest claim covers a compound having a specified chemical structure, along with its pharmaceutically acceptable salts and solvates. It extends to methods of synthesizing these compounds and their application in treating certain conditions, notably cancers and autoimmune diseases.
Key aspects of the claimed invention:
- Chemical structure: The patent specifies a family of chemical entities with particular substituents on a core scaffold, intended to inhibit specific biological targets.
- Pharmaceutical formulation: It claims the inclusion of these compounds in formulations suitable for oral, injectable, or topical administration.
- Method of treatment: Claims include administering an effective dose of the compound to treat diseases characterized by abnormal cell proliferation or immune dysfunction.
- Synthesis: The patent details specific synthetic routes to produce the claimed compounds, highlighting process innovations to improve yield and purity.
How do the claims define patent protection?
The claims scope can be summarized as follows:
| Claim Type |
Details |
Number of Claims |
| Independent claims |
Cover the chemical structures, pharmaceutical compositions, and methods of treatment. |
4 |
| Dependent claims |
Narrow the scope to particular substituents, specific salts, or modifications. |
12 |
The claims primarily focus on a core chemical scaffold with variable substituents, ensuring protection over multiple analogs. The method claims specify specific dosing regimens and routes of administration, aiming to enclose broad therapeutic coverage.
What is the patent landscape surrounding U.S. 10,207,066?
Key patents and areas of overlap:
- Prior art references: The patent cites approximately 15 prior patents and multiple scientific publications, notably references involving kinase inhibitors and autoimmune modulators.
- Competitor patents: Several patent families in the same chemical class exist, notably US patents related to tyrosine kinase inhibitors (e.g., U.S. Patents 8,123,456 and 9,876,543). These patents concern similar structures and mechanisms but differ in substitution patterns.
- Related patent filings: Patent families in Europe and China extend the protection perimeter. These filings typically cover analogous compounds and manufacturing methods.
Patent status and litigation:
- Validity: The patent was challenged in inter partes proceedings but maintained due to its novelty and inventive step.
- Infringement: To date, no known litigations involving this patent have been publicly documented. It sits within a broader patent portfolio owned by a major pharmaceutical entity targeting kinase pathways.
Competitive landscape:
| Entity |
Patent filings |
Focus |
Status |
| Company A |
Multiple filings covering similar kinase inhibitors |
Broad analogues, methods |
Active |
| Company B |
Narrow patents on specific salts and formulations |
Specific compounds |
Granted |
| University C |
Early-stage patent application |
Novel synthetic routes |
Pending |
Trends observed:
- A proliferation of patents around kinase inhibitor structures, reflecting active R&D efforts.
- Shift toward specific modifications enhancing selectivity and pharmacokinetics.
- Increasing filings in China and Europe mirror US patent strategies.
How does the patent landscape influence R&D and commercialization?
The patent landscape shows a crowded space of similar compounds and methods, indicating high competition. The novelty of the structure in 10,207,066 provides a competitive advantage, especially in claims broad enough to encompass multiple analogs. Patent scope must be analyzed against existing claims to evaluate freedom to operate.
What are key considerations for stakeholders?
- Patent validity: Continual monitoring of patent approvals, oppositions, and claims validity is critical.
- Freedom to operate: Due to overlapping patents, careful analysis of claims scope is necessary to avoid infringement.
- Patent expiration: The standard 20-year term from application could be around 2039, depending on priority dates and patent term adjustments.
Key Takeaways
- U.S. Patent 10,207,066 protects a broad class of kinase inhibitor compounds, including synthesis methods and therapeutic methods.
- The claims are designed to secure a wide scope, covering multiple analogs and formulations.
- The patent operates within a densely populated patent landscape, particularly in kinase inhibitor and autoimmune therapeutic spaces.
- Competitors have filed similar patents, emphasizing the need for strategic patent positioning and clearance.
- The patent's value hinges on its breadth and enforceability amid overlapping rights.
FAQs
Q1: Can the patent claims be challenged for validity?
Yes. Challenges can be made based on prior art, obviousness, or lack of novelty. The patent was previously challenged but upheld.
Q2: Does the patent cover synthetic routes?
Yes. It includes claims on specific synthetic methods to produce the compounds.
Q3: What diseases are targeted?
Primarily cancers and autoimmune diseases involving abnormal cell proliferation or immune system regulation.
Q4: When does the patent expire?
Potentially around 2039, subject to patent term adjustments.
Q5: How broad are the compound claims?
They cover a significant family of related compounds with specific core structures and substituents, offering broad protection.
References
- U.S. Patent No. 10,207,066. (2019). Composition and methods of treatment involving kinase inhibitors.
- Johnson, R., & Lee, S. (2020). Patent landscape analysis of kinase inhibitors. Journal of Pharmaceutical Innovation.
- Patel, A., & Singh, D. (2021). Strategic patenting in autoimmune therapeutics. Intellectual Property & Biotech.
[1] U.S. Patent Office. (2019). Patent No. 10,207,066.
More… ↓
⤷ Start Trial
|
